Last reviewed · How we verify

Durvalumab, Gemcitabine, Cisplatin — Competitive Intelligence Brief

Durvalumab, Gemcitabine, Cisplatin (Durvalumab, Gemcitabine, Cisplatin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-L1 inhibitor combined with chemotherapy (gemcitabine and cisplatin). Area: Oncology.

phase 3 PD-L1 inhibitor combined with chemotherapy (gemcitabine and cisplatin) PD-L1 (durvalumab); DNA (gemcitabine and cisplatin) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Durvalumab, Gemcitabine, Cisplatin (Durvalumab, Gemcitabine, Cisplatin) — Akeso. This combination uses durvalumab to block PD-L1 and enhance immune response while gemcitabine and cisplatin provide chemotherapy-induced tumor cell death.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Durvalumab, Gemcitabine, Cisplatin TARGET Durvalumab, Gemcitabine, Cisplatin Akeso phase 3 PD-L1 inhibitor combined with chemotherapy (gemcitabine and cisplatin) PD-L1 (durvalumab); DNA (gemcitabine and cisplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-L1 inhibitor combined with chemotherapy (gemcitabine and cisplatin) class)

  1. Akeso · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Durvalumab, Gemcitabine, Cisplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/durvalumab-gemcitabine-cisplatin. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: